Editas Medicine Inc expected to post a loss of 38 cents a share - Earnings Preview

Editas Medicine

01/08/2025 14:25

Editas Medicine Inc EDIT.OQ EDIT.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2025

The Cambridge Massachusetts-based  company is expected to report a 225.5% increase in revenue to $1.67 million from $513 thousand a year ago, according to the mean estimate from 10 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Editas Medicine Inc is for a loss of 38 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy," 7 "hold" and 2 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Editas Medicine Inc is $3.50, about 28.3% above its last closing price of $2.51

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.61
-0.59
-0.92
Missed
-56.2
Dec. 31 2025
-0.19
-0.36
-0.55
Missed
-54.2
Sep. 30 2024
-0.72
-0.75
-0.75
Met
-0.4​
Jun. 30 2024
-0.73
-0.70
-0.82
Missed
-16.6
​​Mar. 31 2024
-0.66
-0.66
-0.76
Missed
-14.3
Dec. 31 2023
-0.60
-0.54
-0.23
Beat
57.6​
Sep. 30 2023
-0.56
-0.57
-0.55
Beat
3.2
Jun. 30 2023
-0.76
-0.76
-0.56
Beat
26.6

This summary was machine generated August 1 at 13:25 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)